Clinical-stage biopharmaceutical company Apexigen and Brookline Capital Acquisition today announced a definitive business combination agreement that values the merged enterprise at $205 million.
If approved, upon closing Apexigen will continue to be led by President and CEO Xiaodong Yang, and the company expects to list on the Nasdaq under the ticker symbol APGN.
Gross proceeds available to the combined company at closing will be approximately $73 million funded by approximately $58 million in cash held in Brookline Capital’s trust account (assuming no redemptions) and $15 million from a fully committed PIPE that includes participation from healthcare institutional and individual investors. This does not include proceeds from Lincoln Park Capital’s $50 million committed equity line.
In addition, Brookline Capital and Lincoln Park have entered into a committed investment agreement and related registration rights agreement under which the merged company will have the right to direct Lincoln Park to purchase up to an aggregate of $50 million of common stock over a 24-month period.
Apexigen’s wholly owned pipeline is focused on innovative antibody-based therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. Read more.
